Proteomics International Laboratories Ltd (ASX:PIQ) has unveiled landmark clinical data confirming its Promarker(R)Endo blood test as a highly accurate, non-invasive diagnostic tool for endometriosis.
Proteomics International Laboratories Ltd (ASX:PIQ) (OTCMKTS:PIQLF), a pioneer in precision diagnostics, is pleased to announce another milestone in the development of its PromarkerEndo diagnostic test for endometriosis.
AFT Pharmaceuticals Limited (NSX:AFT) (ASX:AFP) today reports it has again achieved another year of record revenue with annual sales exceeding $200 million1 and it is now firmly focused on its revenue target of $300 million by the end of the 2027 financial year.
In this compelling episode of The Ellis Martin Report, host Ellis Martin engages in a powerful and enlightening conversation with Michael Breen, CEO and Managing Director of GT Biopharma Inc. (NASDAQ:GTBP).
Proteomics International Laboratories Ltd ((ASX:PIQ) (OTCMKTS:PIQLF), a pioneer in precision diagnostics, is pleased to announce that its subsidiary OxiDx Pty Ltd, has secured new intellectual property protection following the grant of a patent in China for the platform technology which precisely measures levels of oxidative stress.
Australian-Singaporean regenerative medicine company Osteopore Limited (ASX:OSX) is pleased to announce that the Company has secured a non-exclusive 3-year distribution arrangement with Kelyniam Global, Inc
On 22 April 2025, Proteomics International Laboratories Ltd (ASX:PIQ) (OTCMKTS:PIQLF) announced that it will be conducting a placement of 10,810,811 fully paid ordinary shares in the Company at an issue price of $0.37 per Share to sophisticated, institutional and professional investors, raising approximately $4 million.
